Advice

Supply discontinued

On 31 July 2023 the supply of buprenorphine/naloxone sublingual film (Suboxone) was discontinued and it is therefore no longer available in the UK.

Medicine details

Medicine name:
buprenorphine/naloxone (Suboxone)
SMC ID:
SMC2316
Indication:

Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Suboxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

Pharmaceutical company
Indivior UK Limited
BNF chapter
Central nervous system
Submission type
Abbreviated
Status
Withdrawn
Date advice published
08 February 2021
Additional notes

On 31 July 2023 the supply of buprenorphine/naloxone sublingual film (Suboxone) was discontinued and it is therefore no longer available in the UK.